The Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market research report outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, Oncology, Respiratory, and Ophthalmology which include the indications Multiple Sclerosis, Alzheimer’s Disease, Unspecified Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Age Related Macular Degeneration, and Retinal Degeneration. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Nuclear Factor Erythroid 2 Related Factor 2 pipeline targets constitutes close to 39 molecules. Out of which, approximately 33 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 6, 2, 1, 18, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 2 molecule.
Nuclear Factor Erythroid 2 Related Factor 2 overview
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
For a complete picture of Nuclear Factor Erythroid 2 Related Factor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.